日本脑炎
病毒学
减毒疫苗
dna疫苗
免疫系统
病毒
生物
日本脑炎疫苗
接种疫苗
灭活疫苗
免疫
免疫
维罗细胞
免疫学
脑炎
毒力
基因
遗传学
作者
Jieqiong Li,Hui Chen,Na Wu,Dongying Fan,Guodong Liang,Na Gao,Jing An
出处
期刊:Vaccine
[Elsevier BV]
日期:2013-08-01
卷期号:31 (38): 4136-4142
被引量:18
标识
DOI:10.1016/j.vaccine.2013.06.099
摘要
Vaccination is the most effective countermeasure for protecting individuals from Japanese encephalitis virus (JEV) infection. There are two types of JEV vaccines currently used in China: the Vero cell-derived inactivated vaccine and the live attenuated vaccine. In this study, we characterized the immune response and protective efficacy induced in mice by the inactivated vaccine, live attenuated vaccine and the DNA vaccine candidate pCAG-JME, which expresses JEV prM-E proteins. We found that the live attenuated vaccine conferred 100% protection and resulted in the generation of high levels of specific anti-JEV antibodies and cytokines. The pCAG-JME vaccine induced protective immunity as well as the live attenuated vaccine. Unexpectedly, immunization with the inactivated vaccine only induced a limited immune response and partial protection, which may be due to the decreased activity of dendritic cells and the expansion of CD4+CD25+Foxp3+ regulatory T cells observed in these mice. Altogether, our results suggest that the live attenuated vaccine is more effective in providing protection against JEV infection than the inactivated vaccine and that pCAG-JME will be a potential JEV vaccine candidate.
科研通智能强力驱动
Strongly Powered by AbleSci AI